Starmed Urgent & Family Care, P.A.

Starmed Urgent & Family Care, P.A. was paid $5.24M by Medicaid between Jan 2019 and Dec 2024, across 52 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 49% of everything it billed.

Compared with peers

Next to other Physician Assistant providers in North Carolina

Rank by total paid#3 of 103

Median peer was paid$24K

This provider vs. median221×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	1,345	$61K
2020	30,890	$689K
2021	140,981	$2.26M
2022	86,744	$1.86M
2023	36,393	$207K
2024incomplete	25,183	$167K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	49%	84,906	33,794	$2.57M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	12%	58,452	23,921	$649K
99199	Unlisted special service, procedure or report	8.8%	78,588	46,185	$464K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	7.0%	21,541	13,293	$365K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	4.2%	10,266	3,762	$220K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	3.6%	22,602	14,656	$189K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.9%	12,804	9,743	$150K
0001A		2.0%	5,483	2,577	$104K
0002A		1.6%	4,789	2,193	$84K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	1.3%	2,283	1,488	$66K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	1.0%	3,638	1,857	$55K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	1.0%	1,351	784	$53K

40 more codes

M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	199	$40K
0072A		<1%	1,165	$39K
0071A		<1%	1,129	$38K
0003A		<1%	675	$21K
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	85	$20K
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	<1%	332	$15K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	2,000	$15K
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	<1%	214	$14K
0012A		<1%	662	$10K
0011A		<1%	725	$10K
90837	Psychotherapy session, about an hour	<1%	433	$8K
0073A		<1%	121	$6K
99401		<1%	1,107	$6K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	384	$5K
M0244	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	<1%	21	$4K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	598	$4K
0031A		<1%	241	$4K
0004A		<1%	79	$3K
0013A		<1%	134	$2K
81025		<1%	556	$2K
81002		<1%	1,698	$2K
99051		<1%	74	$1K
0111A		<1%	37	$1K
0112A		<1%	38	$1K
90834	Psychotherapy session, about 45 minutes	<1%	66	$1K
86328		<1%	23	$723.68
90791	Psychiatric diagnostic evaluation	<1%	23	$482.67
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	53	$474.82
86308		<1%	127	$282.32
36415	Collection of venous blood by venipuncture	<1%	415	$279.90
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	202	$253.37
90472	Immunization administration, each additional vaccine (list separately)	<1%	22	$172.90
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	28	$165.30
83986		<1%	33	$13.89
94760		<1%	61	$4.14
3008F		<1%	590	$0.02
S9088	Services provided in an urgent care center (list in addition to code for service)	0%	391	$0.00
Q0222	Injection, bebtelovimab, 175 mg	0%	60	$0.00
99000		0%	18	$0.00
99072		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKENNARD, STACIE (HR)